{
    "clinical_study": {
        "@rank": "88910", 
        "arm_group": [
            {
                "arm_group_label": "MT-1303-Low", 
                "arm_group_type": "Experimental", 
                "description": "MT-1303-Low Dose"
            }, 
            {
                "arm_group_label": "MT-1303-Middle", 
                "arm_group_type": "Experimental", 
                "description": "MT-1303-Middle Dose"
            }, 
            {
                "arm_group_label": "MT-1303-High", 
                "arm_group_type": "Experimental", 
                "description": "MT-1303-High Dose"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives of the study are:\n\n        -  To evaluate the effects of three oral doses of MT-1303 compared to placebo given for a\n           period of 24 weeks in subjects with relapsing-remitting multiple sclerosis (RRMS) on\n           MRI parameters\n\n        -  To evaluate the safety and tolerability of three oral doses of MT-1303 compared to\n           placebo given for a period of 24 weeks in subjects with RRMS."
        }, 
        "brief_title": "Dose-finding Study of MT-1303", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsing-remitting Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  RRMS as defined by the revised McDonald criteria\n\n          -  Evidence of recent MS activity defined as either:\n\n               -  at least one documented relapse in the previous 12 months, OR\n\n               -  a positive gadolinium (Gd)-enhanced MRI scan within 3 months prior to screening,\n                  OR\n\n               -  at least two documented relapses in the previous 24 months with a positive\n                  Gd-enhanced MRI scan within the previous 12 months\n\n          -  Expanded Disability Status Score (EDSS) score \u22650.0 and \u22645.5 points.\n\n        Exclusion Criteria:\n\n          -  Primary progressive, secondary progressive or progressive relapsing MS at screening\n\n          -  Disease duration >15 years combined with an EDSS score \u22642.0\n\n          -  Relapse of MS during the Screening Period\n\n          -  History or known presence of other neurological disorders likely to render the\n             subject unsuitable for the study\n\n          -  History of any of a list of pre-defined cardiovascular diseases\n\n          -  History or known presence of any significant central nervous system, infectious,\n             metabolic, oncological, ophthalmological or respiratory system disease or illness\n             likely to render the subject unsuitable for the study\n\n          -  Previous exposure to any sphingosine 1-phosphate receptor modulator\n\n          -  Receipt of a live vaccine or systemic corticosteroid use within 28 days prior to\n             randomisation\n\n          -  Previous treatment with beta-interferons or glatiramer acetate within 14 days prior\n             to randomisation\n\n          -  Previous treatment with intravenous immunoglobulin, plasmapheresis, certain\n             immunosuppressants, lymphocyte-depleting therapy, total body irradiation or bone\n             marrow transplantation\n\n          -  Need, or likely need for, treatment with Class I or III anti-arrhythmic drugs or with\n             heart-rate-lowering beta-blockers or calcium-channel blockers, or with any other\n             drugs which can reduce the heart rate\n\n          -  Evidence of significant anaemia, thrombocytopenia, leucopoenia or lymphocytopenia,\n             renal or hepatic impairment\n\n          -  Clinically significant electrocardiogram (ECG) findings."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01742052", 
            "org_study_id": "MT-1303-E04"
        }, 
        "intervention": [
            {
                "arm_group_label": "MT-1303-Low", 
                "intervention_name": "MT-1303-Low", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MT-1303-Middle", 
                "intervention_name": "MT-1303-Middle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MT-1303-High", 
                "intervention_name": "MT-1303-High", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "relapsing-remitting multiple sclerosis", 
            "RRMS"
        ], 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zagreb", 
                        "country": "Croatia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Praha", 
                        "country": "Czech Republic"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vantaa", 
                        "country": "Finland"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Budapest", 
                        "country": "Hungary"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kaunas", 
                        "country": "Lithuania"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Katowice", 
                        "country": "Poland"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Moscow", 
                        "country": "Russian Federation"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Belgrade", 
                        "country": "Serbia"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basel", 
                        "country": "Switzerland"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kozyatagi, Istanbul", 
                        "country": "Turkey"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kiev", 
                        "country": "Ukraine"
                    }, 
                    "name": "Research Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Bulgaria", 
                "Canada", 
                "Croatia", 
                "Czech Republic", 
                "Finland", 
                "Germany", 
                "Hungary", 
                "Italy", 
                "Lithuania", 
                "Poland", 
                "Russian Federation", 
                "Serbia", 
                "Spain", 
                "Switzerland", 
                "Turkey", 
                "Ukraine", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase II, Multicentre, Randomised, Double-blind,Parallel Group, Placebo-controlled, Dose-finding Study to Evaluate the Safety and Efficacy of Three Different Oral Doses of MT-1303 Administered for a Period of 24 Weeks in Subjects With Relapsing-remitting Multiple Sclerosis", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The total number of MRI Gd-enhanced T1-weighted lesions", 
            "safety_issue": "No", 
            "time_frame": "Weeks 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01742052"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}